Welcome to our dedicated page for Research Alliance III SEC filings (Ticker: RACC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Research Alliance III's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Research Alliance III's regulatory disclosures and financial reporting.
Research Alliance Holdings III LLC /Cayman reported acquisition or exercise transactions in this Form 4 filing.
Research Alliance Holdings III LLC /Cayman, a director and ten percent owner of Research Alliance Corp III, received a grant of 275,000 Class A Ordinary Shares on May 21, 2026. The shares were valued at $10.00 per share, and the LLC held 275,000 shares directly after this award.
Research Alliance Corp III director and CEO Matthew Hammond reported an acquisition of 275,000 Class A Ordinary Shares at $10.00 per share. The shares are held indirectly through Research Alliance Holdings III LLC, the sponsor entity, which now holds 275,000 shares after this grant or award.
Hammond is the sole director of the sponsor and has voting and investment discretion over these securities, but he disclaims beneficial ownership except for any pecuniary interest he may have. This is a compensation-related acquisition rather than an open-market purchase.
Research Alliance Corporation III, a healthcare-focused special purpose acquisition company, completed its initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share, raising gross proceeds of $75,000,000.
The company also completed a private placement of 275,000 Class A shares to its sponsor at $10.00 per share for $2,750,000. As of May 21, 2026, $75,000,000 of IPO and private placement net proceeds, including a $2,250,000 deferred underwriting commission, were placed in a trust account for the benefit of public shareholders.
In connection with the IPO, Michael F. MacLean and Timothy J. Miller joined the board and its key committees, each holding 39,130 Class B founder shares after a share transfer and capitalization. The company adopted amended constitutional documents and listed its Class A shares on the Nasdaq Capital Market under the symbol RACC.
Research Alliance Corporation III is a newly formed Cayman Islands blank check company conducting an initial public offering of 7,500,000 Class A ordinary shares at $10.00 per share for aggregate gross proceeds of $75,000,000. The proceeds (less permitted interest withdrawals and underwriting items) will be held in a U.S. trust account for use in an initial business combination.
The sponsor purchased founder shares for an aggregate $25,000 and will purchase 275,000 private placement shares at closing for $2,750,000. Public shareholders can redeem shares at the trust-account per-share amount upon a business combination; the company must complete a business combination within 24 months or liquidate. The founder shares will convert into Class A on a one-for-one basis (subject to anti-dilution) and are structured to equal an aggregate 15% as-converted ownership, which the prospectus shows can produce immediate dilution to public investors.